Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.
Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.
In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a phase III clinical trial for chronic low back pain. XTL ran a phase IIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;l. XTL terminated the agreement in 2010. In 2010, Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).